A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Phase 3
675
about 6 years
2–11
30 sites in AR, CA, FL +16
About this study
This trial is testing whether oral upadacitinib or subcutaneous dupilumab is better at controlling moderate to severe atopic dermatitis in children aged 2 to under 12. Participants will receive either upadacitinib (taken daily) or dupilumab (given every 2 or 4 weeks), and it will last for about 2 years, with regular visits to monitor their condition and check for side effects.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dupilumab
- 2.Take Upadacitinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
dupilumab, upadacitinib
oral (Oral Solution)
Primary: Number of Participants with Adverse Events (AEs)
Dermatology